{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6"},{"groupId":"OG001","value":"13.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"description":"Using the RECIST scan data, an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR) which is subsequently confirmed as per RECIST. ORR is defined as the percentage of patients with OR.","groups":[{"description":"Fulvestrant 250 mg Intramuscular Injection every 28 days","id":"OG000","title":"Fulvestrant 250 mg"},{"description":"Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14","id":"OG001","title":"Fulvestrant 500 mg"}],"paramType":"NUMBER","populationDescription":"All patients with measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}